BOSTON--(BUSINESS WIRE)--Nov. 17, 2005--Point Therapeutics, Inc. (NASDAQ:POTP) presented preclinical data on its lead product candidate talabostat, demonstrating anti-tumor activity when combined with either pemetrexed or erlotinib in a non-small lung cancer (NSCLC) xenograft model in immunodeficient mice at a poster session today at the AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA.
